HEIQ PLC

Director's Dealing • Sep 16, 2024

National Storage Mechanism | Additional information

RNS Number : 3136E

HeiQ PLC

16 September 2024

16 September 2024

HeiQ Plc

("HeiQ" or the "Company" or the "Group")

Director's Dealings

HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene technologies, announces that Carlo Centonze, Chief Executive Officer, has purchased 1,000,000 ordinary shares of 5p each in the Company ("Ordinary Shares") at a price of 5p per share.

Further information is set out below pursuant to the requirements of the UK Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mr. Carlo Centonze

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HeiQ plc

b)

LEI

213800IGT65IMJDO4S03

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 5p each

ISIN: GB00BN2CJ299

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

Date	Price(s)	Volume(s)
12 September 2024	5p per share	500,000
13 September 2024	5p per share	500,000

d)

Aggregated information

- Aggregated volume

- Price

1,000,000 shares

5p per share

e)

Date of the transaction

12th and 13th of September 2024

f)

Place of the transaction

London Stock Exchange, Main Market

For further information, please contact:

HeiQ Plc Carlo Centonze (CEO)	+41 56 250 68 50
Cavendish Capital Markets Limited (Broker) Stephen Keys / Callum Davidson	+44 (0) 207 397 8900
SEC Newgate (Media Enquiries) Elisabeth Cowell / Molly Gretton / Tom Carnegie	+44 (0) 20 3757 6882 HeiQ@s ecnewgate .co.uk

About HeiQ

Founded in 2005, HeiQ is a Swiss-based international company that is a global leader in biotech ingredients and specialty chemicals for diverse applications such as textiles, flooring, building materials, glass, plastics, probiotic cleaning, cosmetics, and more. Working with more than 1000 partners in over 60 countries, our goal is to infuse ordinary products with extraordinary qualities, offering our co-creation partners sustainable and disruptive solutions across industries.

Our business model focuses on the commercialization of existing and as well as the incubation of new technologies, driving shareholder value through sales growth, entry into lucrative markets, and disruptive innovation. This model consists of three distinct technology ventures, being HeiQ AeoniQ, HeiQ Xpectra, and HeiQ GrapheneX, and three growth-orientated business units being HeiQ Textiles & Flooring, HeiQ Life Sciences, and HeiQ Antimicrobials.

We have a robust track record of innovation, with over 200 technologies developed in partnership with 300 major brands, including Hanes, Burberry, HUGO BOSS, Lycra, Zara, Itochu, Bosch Siemens, Ecolab, Woellner, Americhem, Lixil, and many more. Our global team comprises about 200 professionals from 30 nationalities across five continents. We're committed to shaping a future where everyday products drive positive change, one innovation at a time.

To learn more about HeiQ and our innovative solutions, visit www.heiq.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFIFITAFIRLIS